<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	Section of Western blotting	
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	Section of Cell culture	
Provide accession number in repository OR		
supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of		N/A
origin, genetic modification status.		No primary
0 70		culture was
		used.

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		N/A
genetic modification status. Provide accession		No animal
number in repository OR supplier name, catalog		was used.
number, clone number, OR RRID		
Animal observed in or captured from the		N/A
field: Provide species, sex and age where		diito
possible		
Model organisms: Provide Accession number		N/A
in repository (where relevant) OR RRID		Ditto

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession		N/A
number if available, and source (including location		No plant
for collected wild specimens)		was used.
Microbes: provide species and strain, unique		N/A
accession number if available, and source		ditto

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or		N/A
equivalent committee(s), provide reference number		No human
for approval.		participant
		was
		involved.
Provide statement confirming informed consent		N/A
obtained from study participants.		ditto
Report on age and sex for all study participants.		N/A
		ditto

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration		N/A
number OR cite DOI in manuscript.		No clinica
		trial was
		involved.
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-		N/A
by-step protocols are available.		All
		protocols
		used is
		public.
Experimental study design (statistics details) State whether and how the following have been	Yes (indicate where provided: section/paragraph)	n/a
done, or if they were not carried out.		
Sample size determination		N/A
·		It was no
		carried
		out
Randomisation		N/A
		ditto
Blinding		N/A
		ditto
Inclusion/exclusion criteria		N/A
		ditto
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was	Section of Statistical analysis	., -
replicated in laboratory	·	
Define whether data describe technical or biological replicates	Section of Figure legend	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of		N/A
authority granting ethics approval (IRB or equivalent committee(s), provide reference number for		ditto
approval.		
Studies involving experimental animals: State details		N/A
of authority granting ethics approval (IRB or		ditto
equivalent committee(s), provide reference number for approval.		
Studies involving specimen and field samples: State if		N/A
relevant permits obtained, provide details of		ditto
authority approving study; if none were required, explain why.		4.20
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,	(N/A
state the authority granting approval and reference		
number for the regulatory approval		

number for the regulatory approval

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is		N/A
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	Section of Statistical analysis	
tests.		

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,		N/A
including protocols for access or restriction on		No new
access.		dataset was
		created.
If data are publicly available, provide accession		N/A
number in repository or DOI or URL.		ditto
If publicly available data are reused, provide		
		N/A
accession number in repository or DOI or URL, where		ditto
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.		
If code is publicly available, provide accession		N/A
number in repository, or DOI or URL.		ditto

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: https://dx.doi.org/10.21037/jgo-21-359	